Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling. |
|
Device | VENTANA PD-L1 (SP263) ASSAY |
Generic Name | Immunohistochemistry assay, antibody, programmed death-ligand 1 |
Applicant | Ventana Medical Systems, Inc. 1910 E. Innovation Park Dr. Tucson, AZ 85755 |
PMA Number | P160046 |
Date Received | 10/20/2016 |
Decision Date | 05/01/2017 |
Product Code |
PLS |
Docket Number | 17M-2768 |
Notice Date | 05/02/2017 |
Advisory Committee |
Pathology |
Clinical Trials | NCT01693562
|
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement Approval for the VENTANA PD-L1 (SP263) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP263 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma tissue stained with OptiView DAB IHC Detection Kit on a VENTANA BenchMark ULTRA instrument.PD-L1 status is determined by the percentage of tumor cells with any membrane staining above background or by the percentage of tumor-associated immune cells with staining (IC+) at any intensity above background. The percent of tumor area occupied by any tumor-associated immune cells (Immune Cells Present, ICP) is used to determine IC+, which is the percent area of ICP exhibiting PD-L1 positive immune cell staining. PD-L1 status is considered High if any of the following are met:1) >= 25% of tumor cells exhibit membrane staining; or,2) ICP > 1% and IC+ ? 25%; or,3) ICP = 1% and IC+ = 100%.PD-L1 High status as determined by VENTANA PD-L1 (SP263) Assay was associated with increased objective response rate (ORR) in a single arm study of IMFINZI (durvalumab). |
Approval Order | Approval Order |
Summary | Summary of Safety and Effectiveness |
Labeling | Labeling
|
Supplements: |
S001 S004 S005 S006 S007 S008 S009 S010 S011 S012 S013 S014 S015 S016 S017 S018 S019 |
|
|